CEPI’s $3.5 billion plan to End Pandemics

CEPI has launched its $3.5bn plan to dramatically reduce or even eliminate the future risk of pandemics and epidemics, potentially averting millions of deaths and trillions of dollars in economic damage.

CEPI’s five-year plan sets out ambitious initiatives to build a future world that is better equipped to deal with these devastating diseases. As part of the plan, CEPI announced its “moonshot” objective to help compress vaccine development timelines to 100 days, about a third of the time that it took the world to develop a COVID-19 vaccine.

CEPI’s investment case may be accessed at https://endpandemics.cepi.net

CEPI also receives public donations through the UN Foundation COVID-19 Solidarity Response Fund: https://covid19responsefund.org/

10 million

10 million

Lives were saved between 2010 and 2015 thanks to vaccines. (WHO, 2017)

$53 billion

$53 billion

The cost of the 2014 Ebola epidemic in west Africa. (C Huber et al, 2018)

$570 billion

$570 billion

The estimated annual global cost of moderately severe to severe pandemics (World Bank, 2017)

$2.8 billion

$2.8 billion

The average minimum cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases. (D Gouglas et al, 2018)

Progress

Support from donors

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome.

Additionally, CEPI has also received support from private sector entities as well as public contributions through the UN Foundation COVID-19 Solidarity Response Fund.

Calls for Proposals successfully announced

Since our launch in 2017, CEPI has announced a number of Calls for Proposals to support the development of candidate vaccines against Middle East Respiratory Syndrome coronavirus (MERS-CoV), Nipah virus, Lassa virus, Rift Valley fever virus, and Chikungunya viruses, as well as rapid-response technologies to develop vaccines against Disease X.

During this period, CEPI has also overseen several scientific breakthroughs in developing vaccines against other infectious diseases, including the first phase 3 trial of a Chikungunya vaccine and the advancement of the first ever Nipah virus and Lassa virus vaccines into phase 1 clinical trials.

Working on COVID-19 vaccine programmes

CEPI has played a central role in the global response to COVID-19, creating the world’s largest portfolio of COVID-19 vaccines and helping to make 2 billion doses equitably accessible to 190 participating economies through COVAX in 2021.

As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future.

CEPI has helped the global science community do something incredible: develop COVID-19 vaccines in less than a year. With the right support, CEPI will continue to accelerate innovation and achieve breakthroughs, helping ensure that everyone has equitable access to lifesaving vaccines.

Bill Gates, Co-Chair

Bill and Melinda Gates Foundation

Norway will continue to mobilise around CEPI and other much-needed building blocks in global health. If anything, the pandemic has reminded all of us that we need better preparedness and response. We have focused on this agenda for a long time. This is not the time to give up. You can count on Norway's continued support.

Erna Solberg, Prime Minister

Government of Norway

Japan has highlighted the importance of pandemic preparedness and Universal Health Coverage. I believe the CEPI will contribute to achieving them through encouraging development of vaccines.

Yasuhisa Shiozaki, Minister of Health, Labour, and Welfare

Government of Japan

The outbreak of diseases like MERS, Ebola, or Lassa fever will continue to pose a threat to many people’s health as long as there are no effective vaccines. This is why we are involved in the CEPI initiative, whose objective is to prevent future epidemics by developing novel vaccines.

Anja Karliczek, Federal Minister of Education and Research

Government of Germany

We know from Ebola, Zika and SARS that epidemics are among the significant threats we face to life, health and prosperity. Vaccines can protect us, but we’ve done too little to develop them as an insurance policy. CEPI is our chance to learn the lessons of recent tragedies, and outsmart epidemics with new vaccine defences. If others join us in supporting CEPI, we can realise our goal of creating a safer world

Dr Jeremy Farrar, Director

The Wellcome Trust

Recent epidemics taught the world the hard way that infectious diseases know no borders. The EU shares the CEPI objective to develop new vaccines that will help prevent and contain future epidemics, and is committed to collaborating with CEPI in joint efforts towards this goal.

Carlos Moedas, EU Commissioner for Research, Science and Innovation

European Commission

The Australian Government is invested in the global effort to fund critical research and development gaps for pandemic preparedness and global health security. Australia is committed to global health, and will continue to build global innovative partnerships and seek out opportunities for international research collaboration. Australia’s contribution to the Coalition of Epidemic Preparedness Innovations, through the Medical Research Future Fund, will assist in the development of vital vaccines suitable for humans that are deploy-ready before an epidemic begins, and ensure we are prepared for future epidemics.

Government of Australia

Invest now

Work with CEPI

Funding opportunities

We create innovative partnerships between public, private, philanthropic, and civil organisations to develop vaccines against diseases with epidemic potential.

We invest in promising vaccine candidates against our priority pathogens and platform technologies that can enable rapid development of vaccines against new and unknown pathogens. We also coordinate activities to improve our collective response to epidemics.

Learn more about our funding opportunities.

CALLS FOR PROPOSALS

We are supporting all areas of vaccine science.

CEPI is investing in vaccine-based solutions that not only protect some of the most vulnerable people in the world but will also help to prevent future pandemics.

Get in touch to find out how your organisation could work with CEPI.

Contact us